1H25 业绩符合我们预期公司公布1H25 业绩：收入2.34 亿元，同比-71.6%，主要由于去年同期产生授权收入；归母净利润亏损5.91 亿元。1H25 业绩符合我们预期。发展趋势耐立克新适应进入医保带来上半年商业化收入高速增长，下半年利沙妥克拉获批上市有望贡献新增长点。得益于2025 年新适应症第一代和第二代TKI 耐药和/或不耐受的CML-CP 进入医保，1H25，耐立克（奥雷巴替尼）收入...
Source Link1H25 业绩符合我们预期公司公布1H25 业绩：收入2.34 亿元，同比-71.6%，主要由于去年同期产生授权收入；归母净利润亏损5.91 亿元。1H25 业绩符合我们预期。发展趋势耐立克新适应进入医保带来上半年商业化收入高速增长，下半年利沙妥克拉获批上市有望贡献新增长点。得益于2025 年新适应症第一代和第二代TKI 耐药和/或不耐受的CML-CP 进入医保，1H25，耐立克（奥雷巴替尼）收入...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.